Lupin Cefdinir powder for Oral Suspension USP — Class II drug recall D-0684-2018
Terminated recall by Lupin Pharmaceuticals Inc., reported 2018-04-25, distributed nationwide. Superpotent Drug
| Recall number | D-0684-2018 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2018-03-27 |
| Classified | 2018-04-17 |
| Reported by FDA | 2018-04-25 |
| Terminated | 2019-04-15 |
| Distributed | Nationwide (US) |
| Quantity | 40,824 bottles |
| Reason classes | potency |
| NDC | 68180-0722, 68180-0722-04, 68180-0722-05, 68180-0722-10, 68180-0722-20, 68180-0723, 68180-0723-04, 68180-0723-05, 68180-0723-10, 68180-0723-20 |
| Lot numbers | 10/18, 11/18, 12/18, F602241, F602577, F700036 |
Product
Lupin Cefdinir powder for Oral Suspension USP, 250 mg/5 mL in (a) 60 mL packs ( NDC 68180-723-20) and (b) 100 mL packs ( 68180-723-10), Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202
Reason for recall
Superpotent Drug
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0684-2018. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.